F

    Fractyl Health, Inc. Common Stock (GUTS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.71
    +0.05 (+7.86%)

    Market Cap: $104.90M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    70%(7/10)
    Avg Surprise
    +7.24%
    Streak
    3 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.12
    Range$-0.13 - $-0.11
    6 analysts
    EPS Revisions
    1
    0
    7d
    4
    0
    30d
    EPS Estimate Drift
    90d ago$-0.16-30.6%
    60d ago$-0.14-15.9%
    30d ago$-0.14-15.9%
    7d ago$-0.14-11.6%
    Current$-0.12
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    Dec 31, 2026
    EPS Consensus$0.09
    Range$0.08 - $0.11
    4 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.09---
    Sep 26EST
    		-$-0.12---
    Jun 26
    		$-0.12$-0.15+20.00%Beat+78.9%
    Mar 26
    		$0.06N/A+114.20%Beat+111.9%
    Dec 25
    		$-0.07N/A+61.11%Beat+86.5%
    Sep 25
    		$-0.71$-0.32-121.88%Miss-65.1%
    Jun 25
    		$-0.57$-0.36-58.33%Miss-58.3%
    Mar 25
    		$-0.49$-0.50+2.00%Beat-188.2%
    Dec 24
    		$-0.52$-0.42-23.81%Miss-
    Sep 24
    		$-0.43$-0.50+14.00%Beat-
    Jun 24
    		$-0.36$-0.46+21.74%Beat-
    Mar 24
    		$-0.17$-0.30+43.33%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.84EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-778.00%ROIC-2427.33%
    Financial Health
    Debt/Equity-3.11xInterest CoverageN/A
    Current Ratio3.15xQuick Ratio3.15x
    Trading Statistics
    Beta2.32Avg Volume1.22M
    52-Week High$2.4452-Week Low$0.38

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.73
    SMA 20$0.70
    SMA 50$0.75
    SMA 200$0.98
    EMA 10$0.72
    EMA 20$0.72
    EMA 50$0.73
    EMA 200$0.90

    MACD

    Line: -0.00Signal: -0.01Hist: 0.00

    ADX

    ADX: 14.9+DI: 15.8-DI: 19.4

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down44.0
    PSAR$0.81

    Bollinger Bands

    Upper Band$0.78
    Lower Band$0.63
    %B Position2098%(Upper)
    Band Width0.55

    RSI (14-Day)

    Neutral
    48.7

    Momentum Oscillators

    Stoch %K37.0
    Stoch %D49.0
    Williams %R-60.1
    ROC (10d)7.7%
    Momentum0.05
    CCI (20d)-15.0
    MFI (14d)58.5

    Volatility Measures

    ATR (14d)$0.06(8.6%)
    StdDev (20d)0.04
    Hist Vol90.2%(High)

    Volume Flow

    VWAP$0.70
    OBV-14.4M
    AD Line8.8M
    CMF (20d)-0.250

    Volume Metrics

    Avg Vol (20d)1.3M
    Vol Ratio0.9x
    VWMA (20d)$0.71

    Pivot Points

    R3$0.84
    R2$0.80
    R1$0.73
    Pivot Point$0.69
    S1$0.62
    S2$0.57
    S3$0.50

    Advanced Oscillators

    TSI-2.58
    Ultimate Osc41.6
    KST-30.14

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total RevenueN/A$0$0$0$0$0$3,000$14,000$43,000$33,000$7,000$36,000
    Cost of RevenueN/AN/A$279,000$290,000$270,000$290,000$-53,000$7,000$24,000$19,000$40,000$109,000
    Gross ProfitN/AN/A$-279,000$-290,000$-270,000$-290,000$3,000$7,000$19,000$14,000$-33,000$-73,000
    Operating Expenses$19.10M$20.82M$23.28M$22.69M$26.08M$24.76M$25.21M$23.80M$23.00M$21.56M$12.95M$13.80M
    R&D$13.81M$15.60M$16.49M$17.46M$21.15M$19.43M$20.28M$19.00M$16.76M$14.42M$10.17M$9.38M
    SG&A$5.28M$5.22M$6.79M$5.24M$4.93M$5.32M$4.93M$4.80M$6.24M$7.13M$2.82M$5.52M
    Operating Income$-19,096,000$-20,820,000$-23,284,000$-22,694,000$-26,079,000$-24,759,000$-25,210,000$-23,794,000$-22,985,000$-21,542,000$-12,981,000$-13,873,000
    Interest Income$0$593,000$645,000$166,000$226,000$503,000$726,000$947,000$1.38M$1.10M$463,000$226,000
    Interest Expense$6.44M$0$20.44M$22.91M$1.81M$0$0$0$0$0$6.20M$1.87M
    Income Before Tax$-25,538,000$9.22M$-43,727,000$-45,603,000$-27,889,000$-23,735,000$-24,970,000$-23,173,000$-17,229,000$-3,322,000$-19,180,000$-15,747,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-25,538,000$9.22M$-43,727,000$-45,603,000$-27,889,000$-23,735,000$-24,970,000$-23,173,000$-17,229,000$-3,322,000$-19,180,000$-15,747,000
    EBITDA$-24,979,000$9.50M$-43,448,000$-45,313,000$-27,619,000$-23,445,000$-24,747,000$-22,964,000$-17,037,000$-3,269,000$-12,943,000$-15,663,000
    EBIT$-25,538,000$9.22M$-43,727,000$-45,603,000$-27,889,000$-23,735,000$-24,970,000$-23,173,000$-17,229,000$-3,322,000$-12,981,000$-15,747,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about GUTS

    News

    Class action filed against Fractyl Health over misleading claims on diabetes therapy efficacy.

    A class action lawsuit has been filed against Fractyl Health, alleging that the company misled investors about the efficacy of its Revita DMR System for type 2 diabetes and obesity. The lawsuit claims Fractyl overstated the therapy's effectiveness and concealed operational issues impacting clinical trials, leading to a significant drop in stock price. Investors who purchased shares between January 2025 and January 2026 are invited to join the lawsuit, with a lead plaintiff deadline of October 20, 2026.

    Pluang•8/25/26•
    Bearish

    Bronstein, Gewirtz & Grossman LLC Urges Fractyl Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

    Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Fractyl Health, Inc. (NASDAQ: GUTS) and its officers, alleging violations of federal securities laws. The lawsuit claims that the company made false and misleading statements about the effectiveness and operational integrity of its Revita treatment and the REMAIN-1 Midpoint Cohort's clinical results between January 13, 2025, and January 29, 2026. Investors who suffered losses are encouraged to join the class action by October 20, 2026, with the firm operating on a contingency fee basis.

    GlobeNewswire•8/25/26•
    Bearish

    Class action lawsuit filed against Fractyl Health over disappointing clinical trial results and stock plunge.

    A class action lawsuit has been filed against Fractyl Health by investors who purchased securities between January 2025 and January 2026. The lawsuit alleges that Fractyl misled investors regarding the effectiveness of its product Revita, following the disclosure of unfavorable six-month clinical trial results that caused a 68% stock drop. Investors have until October 20, 2026, to participate in the case.

    Pluang•8/25/26•
    Bearish

    GUTS INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Fractyl Health, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the Firm

    Holzer & Holzer, LLC has filed a class action lawsuit against Fractyl Health, Inc. (NASDAQ: GUTS) on behalf of investors who purchased shares between January 13, 2025, and January 29, 2026, and incurred losses. The lawsuit alleges that Fractyl made false and misleading statements regarding the efficacy and prospects of its Revita treatment and operational issues at clinical sites. Investors are encouraged to contact the firm to discuss their legal rights, with a lead plaintiff deadline of October 20, 2026.

    The Malone Telegram•8/25/26•
    Bearish

    GUTS Investor Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Fractyl Health, Inc.

    Robbins LLP, a shareholder rights law firm, has filed a class action lawsuit against Fractyl Health, Inc. (NASDAQ: GUTS) on behalf of investors who purchased securities between January 13, 2025, and January 29, 2026. The lawsuit alleges that Fractyl Health misled investors about the efficacy and viability of its Revita DMR System, specifically regarding its effectiveness in treating type 2 diabetes and obesity. This announcement follows a significant stock price drop after the company disclosed disappointing six-month data for its Revita DMR System and subsequent analyst downgrades.

    PR Newswire•8/24/26•
    Bearish

    Frequently Asked Questions About GUTS

    Does GUTS pay dividends?
    Fractyl Health, Inc. Common Stock (GUTS) does not currently pay a regular dividend.
    What is GUTS's market cap?
    Fractyl Health, Inc. Common Stock (GUTS) has a market capitalization of $104.90M with a current stock price of $0.71.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In